Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Integrated transcriptomic analysis reveals lymphatic Icam1-mediated immune dynamics after myocardial infarction.

Created on 16 Nov 2026

Authors

Xue-Ting Chen, Bei-Bei Hu, Zhao Zhang, Zhong-Xiang Chen, Si-Lian Chen, Shu-Xin Su, Zhe Zhang, Cheng Huang, Lei Wang, Kaa-Seng Lai, Jun-Jie Yang, Ye Wang, Xiao-Dong Fang, Zhen Zhang, Juan Shen, Min Zhang

Published in

Zoological research. Volume 47. Issue 3. Pages 691-705. May 18, 2026.

Abstract

Cardiac lymphatic vessels are active regulators of immune surveillance and inflammatory resolution after myocardial injury. Intercellular adhesion molecule-1 (ICAM-1), a cell-surface glycoprotein broadly expressed in endothelial cells, mediates leukocyte adhesion and trafficking during inflammation; however, how Icam1 in lymphatic endothelial cells (LECs) shapes the post-infarction immune microenvironment remains unclear. In this study, an LEC-specific Icam1 conditional knockout ( Icam1cko) model was generated, and single-cell RNA sequencing and spatial transcriptomics were applied to characterize cellular and molecular remodeling at 3, 7, 21, and 42 days post-myocardial infarction (MI). Results showed that loss of Icam1 in LECs increased post-MI inflammation and fibrotic remodeling, indicating aggravated cardiac injury. Integrated transcriptomic analyses revealed broad alterations in cell composition and cell type-specific molecular signatures in the Icam1cko group, with prominent expansion and activation of proinflammatory neutrophil and macrophage subsets. Cell-cell communication analysis indicated that LEC-specific Icam1 deletion disrupted ICAM-dependent immune cell trafficking through lymphatic vessels, thereby impairing inflammatory cell clearance. Accumulated proinflammatory populations further reinforced leukocyte recruitment through CXCL-mediated crosstalk, amplifying immune imbalance within the infarcted myocardium. Collectively, these findings indicate that LEC Icam1 might be a potential therapeutic target for improving post-MI outcomes.

PMID:
42237943
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement